EUCTR2010-023611-34-NL进行中（未招募）不适用
A Phase II Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects with Acute Coronary Syndrome - CHI SQUARE
Cerenis Therapeutics0 个研究点目标入组 500 人开始时间: 2011年5月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female under 75 years of age, acute chest pain and diagnosis of ST segment elevation or non-ST elevation myocardial infarction or unstable angina, clinically indicated coronary angiography, evidence of coronary artery disease, and an appropriate target coronary artery.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects weighing more than 120 kg, uncontrolled diabetes, triglycerides greater than 500 mg/dl, baseline IVUS of unacceptable quality, subjects for whom CABG is planned, hemodynamically or clinically unstable, and ejection fraction less than 35%.
研究者
相似试验
招募中
2 期
Global Prevention of Asthma in Children StudyAllergic RhinitisAsthmaACTRN12607000633482ational Institute of Allergy and Infectious Diseases200
进行中（未招募）
不适用
A Phase II, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Treatment with SA4503, 1 mg or 3 mg Once Daily for 8 Weeks, in Subjects With Major Depressive DisorderMajor Depressive Disorder (MDD)MedDRA version: 9.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSEUCTR2007-002740-16-FIM's Science Corporation150
进行中（未招募）
1 期
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Primary Sjögren's SyndromeEUCTR2016-000101-37-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO120
进行中（未招募）
1 期
A randomized, blinded clinical study comparing the combination durvalumab and olaparib to durvalumab alone for patients with advanced bladder cancernresectable Stage IV Urothelial CancerMedDRA version: 20.0Level: LLTClassification code 10022880Term: Invasive bladder cancer stage IVSystem Organ Class: 100000004864EUCTR2017-004556-27-ESAstraZeneca AB154
进行中（未招募）
1 期
Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Primary Sjögren's Syndromesubjects with moderate to severe Sjögren's syndromeMedDRA version: 19.1Level: LLTClassification code 10040766Term: Sjogren's diseaseSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: LLTClassification code 10042846Term: Syndrome Sjogren'sSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: LLTClassification code 10040765Term: Sjogren'sSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 19.1Level: PTClassification code 10048676Term: Sjogren-Larsson syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2016-000101-37-GRBristol-Myers Squibb International Corporation160